ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies

Liu, Qianzhen; Liu, Zengping; Wan, Rongxue*; Huang, Wenhua*佛山市第一人民医院; 广东医学院; 南方医科大学
Cancers2022-9DOI: 10.3390/cancers14184452
2被引11阅读
引用收藏
分享

摘要

Simple Summary Cellular immunotherapy has achieved great progress in the treatment of hematological malignancies, and cell therapy may become the main force in the treatment of refractory and relapsed malignant tumors in the future. The efficacy of CAR T cells as a potential cell therapy in the treatment of hematological tumors is acknowledged. Given that clinical application strategies for optimizing CAR T-cell therapy are still immature, this article reviews the impact of various application strategies on CAR T-cell therapy. Chimeric antigen receptor (CAR) T cells have been successfully used for hematological malignancies, especially for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Patients who have undergone conventional chemo-immunotherapy and have relapsed can achieve complete remission for several months with the infusion of CAR T-cells. However, side effects and short duration of response are still major barriers to further CAR T-cell therapy. To improve the efficacy, multiple targets, the discovery of new target antigens, and CAR T-cell optimization have been extensively studied. Nevertheless, the fact that the determination of the efficacy of CAR T-cell therapy is inseparable from the discussion of clinical application strategies has rarely been discussed. In this review, we will discuss some clinical application strategies, including lymphodepletion regimens, dosing strategies, combination treatment, and side effect management, which are closely related to augmenting and maximizing the efficacy of CAR T-cell therapy.

学科与关键词

关键词
immunotherapyCAR T-cellefficacyclinical strategiesacute lymphoblastic leukemianon-Hodgkin's lymphoma
相关
加载中…
  • Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
    Xiao, Xinyi; Wang, Yazhuo; Zou, Zhengbang; Yang, Yufei; Wang, Xinyu; Xin, Xin; Tu, Sanfang*; Li, Yuhua*Frontiers in Immunology, 2022, 13: 954235.被引 13
  • CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
    Zhang, Xiaomin; Zhu, Lingling; Zhang, Hui; Chen, Shanshan; Xiao, Yang*Frontiers in Immunology, 2022, 13: 927153.被引 47
  • Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
    Xu, Xinjie; Huang, Shengkang; Xiao, Xinyi; Sun, Qihang; Liang, Xiaoqian; Chen, Sifei; Zhao, Zijing; Huo, Zhaochang; Tu, Sanfang*; Li, Yuhua*Frontiers in Immunology, 2021, 11: 569117.被引 29
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancers
发表日期
2022-09
卷期
第 14 卷, 第 18 期
页码
4452
DOI
10.3390/cancers14184452
期刊等级
2区
成果收录
SCIE
资助标注
Guangdong Basic and Applied Basic Research Foundation [2019A1515011854]; National Natural Science Foundation of China [61427807]; Fujian Province [2012I2004]

作者

  • L

    Liu, Qianzhen (第一作者)

    guangdong med univ · first peoples hosp foshan

  • L

    Liu, Zengping

    guangdong med univ

查看全部 4 位作者收起作者
  • W

    Wan, Rongxue (通讯)

    guangdong med univ

  • H

    Huang, Wenhua (通讯)

    southern med univ · guangdong med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417